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Abstract: The majority of hypertensive patients, especially those with target organ damage, are 
likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce 
their risk of adverse vascular outcomes. The rationale for combination therapy with agents that 
block the renin–angiotensin system (RAS) and a calcium channel blocker (CCB) or diuretic is 
well founded in growing evidence. Recent published trials have shown that the combination 
of an RAS suppressor and a dihydropiridinic CCB would offer additional benefits indepen-
dently of BP reduction. A telmisartan–amlodipine combination has demonstrated significantly 
greater BP reductions compared with each monotherapy component in the overall population, 
and in particular in patients with moderate to severe hypertension and high-risk patients. This 
  combination is well tolerated with a safety profile similar to placebo and is consistent with the 
known safety profile of its monotherapy components.
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Introduction
Cardiovascular disease (CVD) places a significant burden on healthcare providers. 
Despite improvements in morbidity and mortality statistics in some countries over the 
past few decades, atherosclerotic CVD remains the leading cause of morbid events 
and mortality worldwide, with the expectation of an increasing prevalence in devel-
oping countries.1,2 Worldwide, ischemic heart disease and cerebrovascular disease 
are projected to account for 24% of total deaths by 2030.1 In the EU alone, where 
CVD causes 1.5 million deaths each year,3 direct healthcare costs currently amount to 
€105 billion, with 57% of the total due to inpatient care.4 CVD is also associated with 
substantial indirect costs due to lost productivity, with an estimated overall annual 
cost to the EU of around €169 billion.4
High blood pressure (BP) is the single most prevalent risk factor for CVD   worldwide. 
It is responsible for more deaths than any other risk factor.5,6 A   meta-analysis has 
shown that for each increase in systolic BP (SBP) of 20 mm Hg and in diastolic BP 
(DBP) of 10 mm Hg, there is at least a doubling in the risk of mortality from ischemic 
heart disease and stroke.7 Attributed to 54% of cerebrovascular disease and 47% of 
ischemic heart disease worldwide in 2001, high BP was responsible for 7.6 million 
premature deaths or 13.5% of the global total.5 However, only half of this burden was 
in patients with clinical hypertension, indicating that lesser degrees of BP elevation 
remain a cause for concern.5
Patients with elevated BP alone are not considered to be at high risk of a CV event such 
as myocardial infarction (MI) or stroke. However, the presence of hypertension adds to Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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a patient’s CV risk profile when other risk factors are present.8 
“CV   high-risk patients” include those patients with athero-
thrombotic disease, as indicated by a history of MI, stroke, 
transient ischemic attack, or peripheral arterial disease, together 
with patients with multiple risk factors and patients with target 
organ damage associated with type 2 diabetes.9–13 CV high-risk 
patients are in the middle of the spectrum of risk for CVD 
  progression that is referred to as the “CV continuum”.14,15
Although lifestyle intervention can improve a patient’s 
CV risk profile and has a fundamental role in the manage-
ment of all CV high-risk patients,16 pharmacological agents 
that are able to modify the disease processes involved in 
CVD and delay its progression may become instrumental 
in reducing the burden of CVD. In this regard, statins, anti-
platelet therapy, hypoglycemic agents in type 2 diabetes, 
and antihypertensive therapy have all shown a benefit in 
reducing CV risk.17–20 A continuous and linear relationship 
has been shown between BP lowering and reduction in CV 
mortality, with the risk reduction approximately constant 
for any given BP level down to an SBP of 115 mm Hg and 
a DBP of 75 mm Hg for all age groups.7,20 Even a small 
reduction in SBP of 2 mm Hg would predictably lower 
mortality from ischemic heart disease and stroke by 7% and 
10%,   respectively.7 A recent study in patients with type 2 
diabetes has indicated that aggressive BP lowering of SBP 
to ,120 mm Hg, however, may not confer additional benefit 
compared with usual control.21 Similar results have been pub-
lished in African American hypertensive patients.22 A recent 
reappraisal of the European guidelines for management 
of hypertension reinforces the scarce evidence to support 
tighter BP control in order to reduce the risk of CV events 
in hypertensive patients.23
Thus, based on BP-lowering effects alone, the treatment 
of CV high-risk patients with antihypertensive therapy repre-
sents an opportunity to modify CV risk and improve patient 
outcomes. In order to overcome the challenges of achieving 
BP control in these patients,24,25 the ideal antihypertensive 
medication should be safe and well tolerated, provide effica-
cious and long-lasting 24-hour BP reductions as monotherapy 
with additional efficacy when used in combination, and 
reduce or slow the pathological processes that lead to target 
organ damage and CV events.26,27 In this regard, blockade of 
the renin–angiotensin system (RAS) is a potent therapeutic 
approach, offering the potential to reduce organ damage not 
only by reducing BP but also by reducing the inflammatory 
disease that leads to atherosclerosis.28
The majority of hypertensive patients, especially those 
with target organ damage, are likely to require   multiple-drug 
therapy in order to reach BP targets and reduce their risk of 
adverse vascular outcomes.29,30 The rationale for   combination 
therapy with agents that block RAS and a calcium chan-
nel blocker (CCB) or diuretic is well founded.30–33 Recent 
landmark studies, such as ACCOMPLISH (Avoiding 
  Cardiovascular Events Through Combination Therapy in 
Patients Living with Systolic Hypertension) and ASCOT-
BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm), have demonstrated the antihyperten-
sive benefits associated with angiotensin-converting enzyme 
(ACE) inhibitor/CCB combinations.34–36 More recently, the 
combination of an angiotensin receptor blocker (ARB), such 
as valsartan or olmesartan, and amlodipine has been intro-
duced and tested in stage 1 and 2 hypertensive patients as well 
as on those not controlled by monotherapy.37,38
This review will focus on the role of the combina-
tion telmisartan–amlodipine, a potent ARB and the most 
frequently used CCB, to achieve adequate BP targets in 
hypertensive patients.
Pharmacology, rationale for 
combination, and pharmacokinetics 
of fixed-combination telmisartan–
amlodipine
Telmisartan is an orally active nonpeptide that lowers BP 
with once-daily dosing by blocking the type I angiotensin II 
receptor (AT1 receptor), thus selectively inhibiting the pres-
sor effects of the RAS. Telmisartan was approved by the US 
Food and Drug Administration (FDA) in November 1998 
and by the European Commission in December 1998 for 
the treatment of hypertension. More recently, in ONTAR-
GET (Ongoing Telmisartan Alone and in Combination with 
Ramipril Global Endpoint Trial), telmisartan demonstrated 
a noninferior capacity than ramipril to prevent CV events in 
high-risk patients.39 As a consequence of these results, the 
FDA has approved an expanded indication for telmisartan 
that can now be used to reduce the risk of MI, stroke, or death 
from CV causes in patients aged 55 years or older who are 
intolerant to ACE inhibitors but at high risk for CV events.
Amlodipine is a dihydropyridine CCB that inhibits the 
transmembrane influx of calcium ions into vascular smooth 
muscle and cardiac muscle cells. It is a peripheral arterial 
vasodilator that acts directly on vascular smooth muscle to 
cause a reduction in peripheral vascular resistance and reduc-
tion in BP. Amlodipine was approved by the FDA in July 
1992. The first European approval was in July 1989.
The pharmacokinetics of repeated oral doses of 80 mg 
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repeated oral doses of amlodipine 10 mg at steady state 
were studied in a two-way crossover, open, randomized 
design study (trial 1235.2). This study included 38 healthy 
male or female Caucasian volunteers aged 18–50 years. 
A second pharmacokinetic (drug interaction) study (study 
502.126) was also conducted in 12 healthy subjects as part 
of the Micardis® monotherapy development program. This 
open-label, randomized, two-sequence, two-period crossover 
study demonstrated that telmisartan 120 mg had no effect on 
the steady-state pharmacokinetics of amlodipine 10 mg. In 
summary, there is no clinically significant change in systemic 
exposure to telmisartan 80 mg on coadministration of amlo-
dipine 10 mg after dosing both medications to steady state, 
and there is no relevant drug–drug interaction with regard 
to the effect of amlodipine on telmisartan.
Efficacy studies  
and comparative trials
The telmisartan–amlodipine clinical development program 
included a pivotal 8-week, double-blind, randomized, 
placebo-controlled trial with a factorial study design (includ-
ing a large ambulatory blood pressure monitoring [ABPM] 
substudy) to demonstrate the additive nature of combining 
telmisartan and amlodipine across a wide range of doses 
of each of the individual components.40 An analysis of the 
prospectively defined subset of patients with moderate to 
severe hypertension at baseline has also been published.41 
The results of the 24-hour ABPM substudy have also been 
published.42
A total of 2607 patients were enrolled in the factorial 
study between April 2006 and November 2006, and 1461 
patients were randomized and treated for up to 8 weeks. 
A total of 1344 (92%) patients completed the 8-week trial. 
The efficacy analyses were performed on all patients with 
a baseline value and at least one efficacy measurement at 
target dose (n = 1423). Both telmisartan (irrespective of 
amlodipine dosage; P , 0.0001) and amlodipine (irre-
spective of telmisartan dosage; P , 0.0001) significantly 
lowered the in-clinic trough diastolic BP, without evidence 
of counterproductive   telmisartan-by-amlodipine interaction 
at any dosage (not involving patients treated with placebo; 
P = 0.1777). As expected, the greatest least-squares mean 
reductions in in-clinic diastolic and systolic BP were observed 
with combination therapy compared with respective mono-
therapies (Figure 1). The greatest overall reduction in BP 
was observed with the telmisartan 80 mg plus amlodipine 
10 mg combination (mean reduction in systolic BP⁄diastolic 
BP: −26.4 mm Hg⁄−20.1 mm Hg; P , 0.05 vs both 
monotherapies).40 More than 50% of all patients treated with 
combination therapy achieved BP control (diastolic BP , 
90 mm Hg and systolic BP , 140 mm Hg), with the highest 
percentages (76.5% [overall control] and 85.3% [diastolic BP 
control]) being achieved by patients treated with telmisartan 
80 mg plus amlodipine 10 mg. Diastolic BP response and 
systolic BP response was achieved by 91.2% and 90.4% of 
patients in the telmisartan 80 mg plus amlodipine 10 mg group, 
  respectively.40 This combination was also effective in patients 
with moderate or severe hypertension. In fact, the greatest 
reduction in BP (SBP/DBP −26.5 ± 1.2/−21 ± 0.8 mm Hg) 
was achieved with the highest-dose combination of telmisar-
tan 80 mg plus amlodipine 10 mg and the SBP/DBP response 
rates .90%. The BP control (,140/90 mm Hg) and DBP 
control (,90 mm Hg) obtained with this combination was 
77% and 85%, respectively.41
The largest reductions in 24-hour mean BP were observed 
with the combination of telmisartan 80 mg and amlodipine 
10 mg when compared with their respective monotherapies 
(P , 0.0001 in each comparison): telmisartan 80 mg and 
amlodipine 10 mg (−22.4/−14.6 mm Hg), telmisartan 80 mg 
(−11.0/−6.9 mm Hg), and amlodipine 10 mg (−11.9/−6.9 mm Hg). 
Greater BP reductions were also observed for the combinations 
of lower doses of telmisartan (40 mg) and amlodipine (5 mg) in 
combination compared with the components.42
Fogari et al43 evaluated the effect of a combination 
therapy with telmisartan and amlodipine on urinary albumin 
excretion rate (UAER) in hypertensive patients with type 2 
diabetes and microalbuminuria and examined whether two 
different dose regimens (high-dose telmisartan/low-dose 
amlodipine and vice versa) offered different benefits in 
terms of reduction of proteinuria. After a 2-week placebo 
washout period, during which antihypertensive but not oral 
antidiabetic drugs were discontinued, patients fulfilling the 
inclusion criteria were treated with the telmisartan (40 mg)/
amlodipine (2.5 mg) combination. After 4 weeks, patients 
whose BP was not controlled (BP . 130/80 mm Hg) were 
enrolled in the study and randomized to two different dose 
titration regimens: one based on increasing doses of telm-
isartan (40 mg every 4 weeks until 160 mg) and a fixed 
2.5 mg dose of amlodipine (group T), the other based on an 
increasing dose of amlodipine (2.5 mg every 4 weeks until 
10 mg) and a fixed 40 mg dose of telmisartan (group A). After 
16 weeks, the nonresponder patients were given 0.1 mg/day 
transdermic clonidine.43 High-dose telmisartan/low-dose 
amlodipine and low-dose telmisartan/high-dose amlodipine 
combinations produced similar reductions in systolic and dia-
stolic BP values, with no significant differences between the Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Segura and Ruilope
two regimens at any time of the study. With increasing doses 
of telmisartan (from 40 mg to 80 mg, 120 mg, and 160 mg), 
systolic/diastolic BP values were reduced from baseline 
by 16/10 mm Hg (P , 0.01 vs baseline), 24/21 mm Hg, 
23/21 mm Hg, and 24/21 mm Hg (all P , 0.001 vs baseline), 
respectively. With increasing doses of amlodipine (from 
2.5 mg to 5 mg, 7.5 mg, and 10 mg), systolic/diastolic BP val-
ues were reduced from baseline by 16/10 mm Hg (P , 0.01 
vs baseline), 25/22 mm Hg, 25/21 mm Hg, and 25/22 mm 
Hg (all P , 0.001 vs baseline), respectively. The UAER 
was significantly decreased from baseline by both combina-
tion regimens, but such a decrease was significantly more 
marked in the T group (Figure 2). Reductions of UAER from 
baseline were of 34.6 mg/24 hours (P , 0.05 vs baseline), 
62.9 mg/24 hours (P , 0.01 vs baseline and P , 0.05 vs 
A group), 86.5 mg/24 hours (P , 0.001 vs baseline and 
P , 0.01 vs A group) and 102 mg/24 hours (P , 0.0001 vs 
baseline and P , 0.001 vs A group) for telmisartan 40 mg, 
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Figure 1 effect of 8 weeks of treatment with telmisartan (T) 0 mg, 20 mg, 40 mg, and 80 mg plus amlodipine (A) 0 mg, 2.5 mg, 5 mg, and 10 mg on the change from baseline 
in the in-clinic seated trough (A) diastolic blood pressure (DBP) (mm Hg) or (B) systolic blood pressure (SBP) (mm Hg).
Notes: *P , 0.05 vs T monotherapy; †P , 0.05 vs A monotherapy. Data are least-squares mean (standard error) values adjusted for dosage, country/region, and baseline 
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Figure 2 Percentage of urinary albumin excretion rate (UAeR) decrease with telmisartan–amlodipine combination at different doses.
Notes: ˆp <0.05, ˆˆp <0.0001, ºp <0.03 ºp <0.01, ººp <0.001, Change from baseline; §p <0.05; §§p <0.01, §§§p <0.001, between treatment, +p <0.05 vs 80/2.5.
80 mg, 120 mg, and 160 mg/amlodipine 2.5 mg daily, 
respectively. Reductions of UAER from baseline were of 
35.1 mg/24 hours (P , 0.05 vs baseline), 46.2 mg/24 hours 
(P , 0.03 vs baseline), 50.3 mg/24 hours (P , 0.03 vs 
baseline), and 45 mg/24 hours (P , 0.03 vs baseline) for 
amlodipine 2.5 mg, 5 mg, 7.5 mg, and 10 mg/telmisartan 
40 mg daily, respectively.43
Safety and tolerability
In the factorial study, a total of 545 (37.3%) patients reported 
at least one adverse event during the 8-week study.40 When 
analyzed by treatment groupings, the percentage of patients 
reporting adverse events on specific treatment was compa-
rable: placebo (39.1%, n = 18), telmisartan monotherapy 
(36.8%, n = 113), amlodipine monotherapy (36.1%, n = 115), 
and combination therapy (37.9%, n = 299) groups. The most 
commonly reported adverse events were headache (5.4%, 
n = 79) and peripheral edema (4.4%, n = 65). Headache was 
more frequent in the placebo group (10.9%, n = 5) compared 
with the telmisartan monotherapy (5.9%, n = 18), amlodipine 
monotherapy (6.0%, n = 19), and combination therapy (4.7%, 
n = 37) groups. The incidence of peripheral edema was high-
est in the amlodipine 10 mg group (17.8%, n = 23); however, 
this rate was lower when amlodipine was used in   combination 
with telmisartan: 11.4% (telmisartan 20 mg/amlodipine 
10 mg), 6.2% (telmisartan 40 mg/  amlodipine 10 mg), and 
11.3% (telmisartan 80 mg/amlodipine 10 mg) (Figure 3).
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability, adherence, and uptake
Hypertension is a chronic disease for which there is no cure. 
Antihypertensive medications will lower BP in patients for 
as long as patients comply with therapy. Poor patient adher-
ence with health-related advice, medication, tests, and clinic 
appointments has been reported as the most common cause of 
nonresponse to medication.44 Poor adherence to medication 
regimens is a major contributor to the gap between practice 
guidelines and clinical outcome in CVD.45–47 Poor persistence 
may be affected by many patient-related factors. Poor moti-
vation to accept treatment can lead to a cycle of treatment 
failure. Patients and physicians frequently accept failure of 
initial treatment and lack the motivation to continue treating 
the condition. Patients may embark on a series of treatment 
steps, each viewed as a failure, further undermining motiva-
tion and fulfilling negative expectations, resulting in poor BP 
control and an increased risk of mortality and morbidity for 
the patient. In consequence, poor compliance and persistence Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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with medication by patients results in poor clinical outcomes. 
Given the scale of the problem and its effect on everyday 
practice, it is essential to develop and implement strategies 
to improve compliance.
Persistence rates with currently available classes of 
antihypertensive medications vary widely. Patients pre-
scribed ARBs as their initial medication are more likely 
to persist with treatment than patients on other classes of 
  antihypertensive.48 Moreover, it has been confirmed that the 
treatment discontinuation rate differs between antihyper-
tensive drug classes. The treatment discontinuation rate is 
lowest in patients in whom the drug initially prescribed was 
an ARB, and became progressively greater with the initial 
administration of an ACE inhibitor, a CCB, an α-blocker, 
a β-blocker, and a diuretic.49
The use of multiple medications and complexity of treat-
ment regimen are two of the major determinants of poor 
medication adherence. A survey conducted by the National 
Council on Patient Information and Education showed that 
one-third of patients receive at least two prescriptions and 
10% of patients receive four or more prescriptions after a 
visit to a primary care physician.50 In a systematic review 
of the impact of dose regimen on medication compliance, 
it has been shown that dose taking was inversely related to 
the prescribed number of doses per day. Compliance was 
significantly higher for once daily versus three times daily 
(P = 0.008), once daily versus four times daily (P , 0.001), 
and twice daily versus four times daily (P = 0.001) 
regimens.51 Adherence to antihypertensive agents varies 
inversely with dosing frequency,52 and nonadherent patients 
tend to have higher BP than adherents.53 As adherence rates 
are inversely related to the number of drugs given, it would 
be expected that patients would be more adherent when they 
take a combination of drugs as a single tablet than if they are 
given the same drugs as two separate pills, even when dosed 
once daily.54,55 In the 2009 reappraisal of European guide-
lines on hypertension management, the European Society of 
Hypertension Task Force notes: “Whenever possible, use of 
single pill (or single pill) combinations should be preferred, 
because simplification of treatment carries advantages for 
compliance to treatment”.23
Conclusion
Adequate BP control and reduction of CV events are par-
ticularly effective with the combination of antihypertensive 
agents, including an ACE inhibitor or an ARB. Recently, the 
combination of an ACE inhibitor or ARB plus a CCB appears 
to be rational and effective. These combinations can thus be 
recommended for priority use. Telmisartan–amlodipine com-
bination has demonstrated significantly larger DBP and SBP 
reductions compared with each monotherapy component in the 
overall population, and in particular in patients with moderate 
to severe hypertension. This combination is well tolerated with 
a safety profile similar to placebo and is consistent with the 
known safety profile of its monotherapy components.
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